The recently described pDC-AML constitutes about 3–5% of all AMLs and has been shown to be characteristically enriched in RUNX1 mutations, in addition to harboring other clonal hematopoiesis-related mutations [8,9]. The gene discussed is RUNX1; the disease is acute myeloid leukemia.